Biotech · Private company
Glycomine, Inc.
Track this companyFree. Adds Glycomine, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials42 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- GLM101 (Part A, Double-blind)Phase 3 · Phosphomannomutase 2 DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- GLM101 (Part B, Open-label)Phase 3 · Phosphomannomutase 2 DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- GLM101Phase 2 · Pmm2-CDGClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDGPHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Jul 9, 2025ClinicalTrials.gov NCT06892288 · fetched Nov 12, 2026
- Open-Label Extension Study to Assess GLM101 in PMM2-CDG PatientsPHASE2 · ENROLLING_BY_INVITATION · started Sep 30, 2024ClinicalTrials.gov NCT06657859 · fetched Nov 12, 2026
- 24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDGPHASE2 · COMPLETED · started Nov 29, 2022ClinicalTrials.gov NCT05549219 · fetched Nov 12, 2026
- Natural History Study Protocol in PMM2-CDG (CDG-Ia)COMPLETED · started Jan 8, 2018ClinicalTrials.gov NCT03173300 · fetched Nov 12, 2026